Silexion Therapeutics Corp - Warrant — Quarterly Balance Sheet (NASDAQ:SLXNW)

Financials

Total revenue 48 K24 K-5 00049 K30 K 98 K Gross profit 48 K202 K-81 K-211 K22 K -68 K Operating expenses 8.04 M1.9 M1.65 M2.28 M3.29 M 9.13 M Selling/general/admin expenses 4.82 M1.03 M1.06 M1.27 M1.14 M 4.49 M Research & development 3.22 M871 K590 K1.02 M2.16 M 4.64 M Operating income 8.04 M1.9 M1.65 M2.28 M3.29 M 9.13 M Non-Operating Income, Total 3.82 M-154 K85 K216 K-30 K 117 K Interest expense, net of interest capitalized -1.75 M01.74 M2.5 M3.26 M 7.5 M Non-Operating Income, excl. Interest Expenses 5.57 M-156 K-1.65 M-2.29 M-3.3 M -7.39 M Unusual income/expense 3 0002 0003 00004 000 9 000 Pretax income -11.86 M-1.75 M-1.74 M-2.5 M-3.26 M -9.24 M Equity in earnings ————— — Taxes 2 0001 00003 0000 4 000 Non-controlling/minority interest 9 0000000 0 After tax other income/expense -3.75 M—-81 K-229 K16 K — Net income before discontinued operations 11.86 M1.75 M1.74 M2.5 M3.26 M 9.25 M Discontinued operations ————— — Net income 11.86 M1.75 M1.74 M2.5 M3.26 M 9.25 M Dilution adjustment ————— — Preferred dividends ————— — Diluted net income available to common stockholders 11.85 M1.75 M1.74 M2.5 M3.26 M 9.25 M Basic earnings per share (Basic EPS) 374.91-359.453.94.312.15 -349.09 Diluted earnings per share (Diluted EPS) 374.91-359.453.94.312.15 -349.09 Average basic shares outstanding 19.43 K41.59 K451.95 K516.11 K723.89 K 1.73 M Diluted shares outstanding 19.43 K41.59 K451.95 K516.11 K723.89 K 1.73 M EBITDA —-1.71 M-1.73 M-2.49 M-3.27 M -9.2 M EBIT —-1.7 M-1.73 M-2.5 M-3.27 M -9.19 M Cost of revenue —-178 K76 K260 K8 000 166 K Other cost of goods sold ————— — Depreciation & amortization (cash flow) 22 K-12 K4 0003 0004 000 -1 000